Literature DB >> 788154

Antibacterial synergism: a proposal for chemotherapeutic potentiation between trimethoprim and sulfamethoxazole.

M Poe.   

Abstract

Sulfamethoxazole and other sulfa drugs are moderately potent inhibitors of Escherichia coli dihydrofolate reductase. They also significantly potentiate the inhibition of this enzyme by trimethoprim. The molecular basis for inhibition potentiation is the simultaneous binding of trimethoprim and sulfa by the enzyme. This potentiation may explain the synergism observed when these drugs are used in antibacterial chemotherapy.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 788154     DOI： 10.1126/science.788154

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  10 in total

Review 1.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

2.  Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiae.

Authors:  V H Brophy; J Vasquez; R G Nelson; J R Forney; A Rosowsky; C H Sibley
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

3.  Bactericidal activity of trimethoprim alone and in combination with sulfamethoxazole on susceptible and resistant Escherichia coli K-12.

Authors:  S G Amyes
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

4.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

5.  Interactions between inhibitors of dihydrofolate reductase.

Authors:  K Bowden; A D Hall; B Birdsall; J Feeney; G C Roberts
Journal:  Biochem J       Date:  1989-03-01       Impact factor: 3.857

6.  Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole.

Authors:  Oh Chan Kwon; Jung Sun Lee; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo; Seokchan Hong
Journal:  Clin Rheumatol       Date:  2018-01-30       Impact factor: 2.980

7.  Potentiating effect of pyrimethamine and sulfadoxine against dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant Plasmodium chabaudi.

Authors:  W Sirawaraporn; Y Yuthavong
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 8.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

9.  Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain.

Authors:  A Nzila-Mounda; E K Mberu; C H Sibley; C V Plowe; P A Winstanley; W M Watkins
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

10.  Synergy of vancomycin with penicillins and cephalosporins against pseudomonas, klebsiella, and serratia.

Authors:  H Donabedian; V T Andriole
Journal:  Yale J Biol Med       Date:  1977 Mar-Apr
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.